Influence of IL-28B and IL-6 Genetic Polymorphism on IFN-ALFA Treatment Outcome in Patients with Polycythemia Vera and Essential Trombocythemia

Marie Lindgren(Umeå University), Björn Andréasson(NU Hospital Group), Anna Hugosson(Skaraborg Hospital), Fredrik Nilsson, Waleed Ghanima(Oslo University Hospital), Maria Åström(Örebro University Hospital), Jessica Samuelsson(Karolinska Institutet), Lars Palmqvist(Sahlgrenska University Hospital), Johan Westin(University of Gothenburg), Håvar Knutsen(Akershus University Hospital), Elisabeth Ejerblad(Uppsala University)
Unknown
January 1, 2014
Cited by 0

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia
|Blood|2008|447
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194